Why Is Liver Disease-Focused Inventiva Stock Trading Lower Today?
Portfolio Pulse from Vandana Singh
Inventiva SA (NASDAQ:IVA) stock is trading lower after announcing a voluntary pause in screening and randomization of new patients in the NATiV3 Phase 3 trial of lanifibranor for non-alcoholic steatohepatitis (NASH) due to a treatment-related adverse reaction. This pause may extend the trial's timeline, but the company's financials remain stable with a cash runway until Q3 2024. IVA shares dropped 20.1% to $3.15.
February 16, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Inventiva SA announced a pause in its NATiV3 Phase 3 trial due to a serious adverse reaction, potentially delaying the trial's timeline. Despite this, the company's financial position remains stable, with a cash runway until Q3 2024.
The voluntary pause in the NATiV3 trial due to a serious adverse reaction is a significant development, likely causing concern among investors and leading to a 20.1% drop in IVA shares. However, the company's stable financial position, including a cash runway until Q3 2024, may mitigate some concerns over the long term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100